T J Kowalski1, W L Berth, M A Mathiason, W A Agger. 1. Section of Infectious Disease, Gundersen Lutheran Health System, 1900 South Avenue, La Crosse, WI 54601, USA. TJKowals@gundluth.org
Abstract
PURPOSE: To study the long-term functional outcomes of patients with Lyme facial nerve palsy treated with oral antibiotics. METHODS: We conducted a retrospective double-cohort study involving patients with Lyme facial nerve palsy treated with oral antibiotics matched to three controls with early localized Lyme disease. Chart review was completed and an SF-36 health questionnaire and standardized symptom questionnaire administered. RESULTS: Lyme facial nerve palsy patients were treated with oral antibiotics for a median duration of 21 days (range 7-30 days). Only three patients underwent lumbar puncture and each demonstrated lymphocytic pleocytosis. Fourteen of 15 patients with Lyme facial nerve palsy completely regained nerve function. The long-term outcomes were similar between patients with Lyme facial nerve palsy and controls after a median follow-up duration of 4.6 years. Patients with Lyme facial nerve palsy had significantly higher reported rates of fatigue (60%) than controls (27%) (p = 0.019), but similar energy and vitality scores on the SF-36 questionnaire (55.0 vs. 58.4, p = 0.621). SF-36 social functioning domain scores were significantly lower in patients with Lyme facial nerve palsy (77.5) than in controls (88.6) (p = 0.044). There were no other significant differences noted between the two cohorts. CONCLUSIONS: For patients with Lyme facial nerve palsy in North America, treatment with oral doxycycline appears to be an effective therapeutic strategy.
PURPOSE: To study the long-term functional outcomes of patients with Lyme facial nerve palsy treated with oral antibiotics. METHODS: We conducted a retrospective double-cohort study involving patients with Lyme facial nerve palsy treated with oral antibiotics matched to three controls with early localized Lyme disease. Chart review was completed and an SF-36 health questionnaire and standardized symptom questionnaire administered. RESULTS:Lyme facial nerve palsypatients were treated with oral antibiotics for a median duration of 21 days (range 7-30 days). Only three patients underwent lumbar puncture and each demonstrated lymphocytic pleocytosis. Fourteen of 15 patients with Lyme facial nerve palsy completely regained nerve function. The long-term outcomes were similar between patients with Lyme facial nerve palsy and controls after a median follow-up duration of 4.6 years. Patients with Lyme facial nerve palsy had significantly higher reported rates of fatigue (60%) than controls (27%) (p = 0.019), but similar energy and vitality scores on the SF-36 questionnaire (55.0 vs. 58.4, p = 0.621). SF-36 social functioning domain scores were significantly lower in patients with Lyme facial nerve palsy (77.5) than in controls (88.6) (p = 0.044). There were no other significant differences noted between the two cohorts. CONCLUSIONS: For patients with Lyme facial nerve palsy in North America, treatment with oral doxycycline appears to be an effective therapeutic strategy.
Authors: Daniel Cameron; Andrea Gaito; Nick Harris; Gregory Bach; Sabra Bellovin; Kenneth Bock; Steven Bock; Joseph Burrascano; Constance Dickey; Richard Horowitz; Steven Phillips; Laurence Meer-Scherrer; Bernard Raxlen; Virginia Sherr; Harold Smith; Pat Smith; Raphael Stricker Journal: Expert Rev Anti Infect Ther Date: 2004 Impact factor: 5.091
Authors: Henry M Feder; Barbara J B Johnson; Susan O'Connell; Eugene D Shapiro; Allen C Steere; Gary P Wormser; W A Agger; H Artsob; P Auwaerter; J S Dumler; J S Bakken; L K Bockenstedt; J Green; R J Dattwyler; J Munoz; R B Nadelman; I Schwartz; T Draper; E McSweegan; J J Halperin; M S Klempner; P J Krause; P Mead; M Morshed; R Porwancher; J D Radolf; R P Smith; S Sood; A Weinstein; S J Wong; L Zemel Journal: N Engl J Med Date: 2007-10-04 Impact factor: 91.245
Authors: Gary P Wormser; Raymond J Dattwyler; Eugene D Shapiro; John J Halperin; Allen C Steere; Mark S Klempner; Peter J Krause; Johan S Bakken; Franc Strle; Gerold Stanek; Linda Bockenstedt; Durland Fish; J Stephen Dumler; Robert B Nadelman Journal: Clin Infect Dis Date: 2006-10-02 Impact factor: 9.079
Authors: Gary P Wormser; Donna McKenna; Jennafer Carlin; Robert B Nadelman; L Frank Cavaliere; Diane Holmgren; Daniel W Byrne; John Nowakowski Journal: Ann Intern Med Date: 2005-05-03 Impact factor: 25.391
Authors: J J Halperin; E D Shapiro; E Logigian; A L Belman; L Dotevall; G P Wormser; L Krupp; G Gronseth; C T Bever Journal: Neurology Date: 2007-05-23 Impact factor: 9.910
Authors: Sebastian Rauer; Stephan Kastenbauer; Heidelore Hofmann; Volker Fingerle; Hans-Iko Huppertz; Klaus-Peter Hunfeld; Andreas Krause; Bernhard Ruf; Rick Dersch Journal: Ger Med Sci Date: 2020-02-27
Authors: Siu P Turk; Keith Lumbard; Kelly Liepshutz; Carla Williams; Linden Hu; Kenneth Dardick; Gary P Wormser; Joshua Norville; Carol Scavarda; Donna McKenna; Dean Follmann; Adriana Marques Journal: PLoS One Date: 2019-11-11 Impact factor: 3.240